Publications

COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery.

Toor, J; Li, X; JIT, M; Trotter, C; Echeverria-Londono, S; Hartner, A-M; Roth, J; Portnoy, A; Abbas, K; Ferguson, N; Gaythorpe, KA M;

2022

medRxiv (2022). 10.1101/2022.01.07.22268891.

Solidarity COVID-19 vaccine trial.

WATSON-JONES, D;

2022

(2022).

End-point definition and trial design to advance tuberculosis vaccine development.

Garcia-Basteiro, AL; WHITE, RG; Tait, D; Schmidt, AC; Rangaka, MX; Quaife, M; Nemes, E; Mogg, R; Hill, PC; Harris, RC; Hanekom, WA; Frick, M; Fiore-Gartland, A; Evans, T; Dagnew, AF; Churchyard, G; Cobelens, F; Behr, MA; Hatherill, M;

2022

European respiratory review, (2022).31 164 10.1183/16000617.0044-2022.

Review of Existing Evidence on Single Dose Vaccination.

WATSON-JONES, D;

2022

(2022).

Immunogenicity and immunobridging of single dose HPV vaccine in Tanzanian girls – the DoRIS trial.

WATSON-JONES, D;

2022

(2022).

Immune Response of a Two-dose, Heterologous Ebola Vaccine Regimen Using a 'One Assay, One Lab' Approach: Summary of Three African Clinical Trials.

WATSON-JONES, D;

2022

(2022).

Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.

Horne, EM F; Hulme, WJ; KEOGH, RH; Palmer, TM; WILLIAMSON, EJ; PARKER, EP K; Green, A; Walker, V; Walker, AJ; Curtis, H; Fisher, L; MacKenna, B; Croker, R; Hopcroft, L; Park, RY; Massey, J; Morley, J; Mehrkar, A; Bacon, S; Evans, D; Inglesby, P; Morton, CE; Hickman, G; Davy, S; Ward, T; ... Sterne, JA C.

2022

British Medical Journal, (2022).378, 10.1136/bmj-2022-071249.

NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans.

Wagstaffe, HR; Anzala, O; Kibuuka, H; ANYWAINE, Z; Sirima, SB; Thiébaut, R; Richert, L; Levy, Y; Lacabaratz, C; Bockstal, V; Luhn, K; Douoguih, M; GOODIER, MR;

2022

Vaccines, (2022).10 6 10.3390/vaccines10060884.

The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries.

Portnoy, A; Arcand, J-L; Clark, R; WEERASURIYA, C; Mukandavire, C; Bakker, R; Patouillard, E; Gebreselassie, N; Zignol, M; JIT, M; WHITE, R; Menzies, N;

2022

medRxiv (2022). 10.1101/2022.11.23.22282690.

Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.

Li, X; Bilcke, J; Vázquez Fernández, L; Bont, L; Willem, L; Wisløff, T; JIT, M; Beutels, P; REspiratory Syncytial virus Consortium in EUrope (,;

2022

The Journal of infectious diseases, (2022).226 Suppl 1 10.1093/infdis/jiac064.